XML 99 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2013
STOCK BASED COMPENSATION  
Schedule of stock based compensation expense

Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three and six months ended June 30, 2012 and 2013 as shown in the following table (in $000s):

 

 

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

 

 

2012

 

2013

 

2012

 

2013

 

General and administrative

 

$

66

 

$

60

 

$

142

 

$

117

 

Research and development

 

16

 

14

 

33

 

29

 

Discontinued operations

 

27

 

 

36

 

 

Stock-based compensation costs before income taxes

 

$

109

 

$

74

 

$

211

 

$

146

 

Schedule of stock option activity

Cyclacel Pharmaceuticals, Inc.

 

Number of
options
outstanding

 

Weighted
average
exercise
price

 

Weighted
average
remaining
contractual
term (years)

 

Aggregate
intrinsic
value ($000)

 

Options outstanding at December 31, 2012

 

463,023

 

$

26.61

 

5.58

 

$

347

 

Granted

 

32,697

 

$

3.01

 

 

 

 

 

Exercised

 

 

$

 

 

 

 

 

Cancelled/forfeited

 

(8,001

)

$

17.10

 

 

 

 

 

Options outstanding at June 30, 2013

 

487,719

 

$

25.18

 

5.46

 

3

 

Unvested at June 30, 2013

 

85,606

 

$

6.47

 

8.78

 

 

Vested and exercisable at June 30, 2013

 

402,113

 

$

29.20

 

4.76

 

3

 

Schedule of restricted stock units activity

 

 

Restricted Stock
Units

 

Weighted Average
Grant
Date Value Per Share

 

Non-vested at December 31, 2012

 

39,377

 

$

5.34

 

Granted

 

85,097

 

$

5.71

 

Forfeited

 

(1,331

)

$

3.85

 

Non-vested at June 30, 2013

 

123,143

 

$

5.61